UPDATE: COVID-19 Read the Message

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jan 14, 2021
- New category targets programs that support the transition from adolescence to adulthood - - Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 - SOUTH PLAINFIELD, N.J. , Jan. 14, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh
Additional Formats
Jan 13, 2021
SOUTH PLAINFIELD, N.J. , Jan. 13, 2021 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of 13,465 shares of its common stock and 4,665 restricted stock units ("RSUs"), each representing
Additional Formats
Jan 11, 2021
- ~$333 million preliminary unaudited 2020 total net product revenue representing 14% year-over-year growth - - Huntington splicing program healthy volunteer data expected 1H 2021 - - Multiple late-stage clinical programs advancing with six registration-directed trials - - 2021 Duchenne franchise
Additional Formats
Jan 04, 2021
SOUTH PLAINFIELD, N.J. , Jan. 4, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11 th at 7:30 a.m. EST .
Additional Formats
Dec 18, 2020
SOUTH PLAINFIELD, N.J. , Dec. 18, 2020 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on December 15, 2020 it approved non-statutory stock options to purchase an aggregate of 12,500 shares of its common stock and 4,360 restricted stock units ("RSUs"), each representing
Additional Formats
Dec 09, 2020
SOUTH PLAINFIELD, N.J. , Dec. 9, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing Translarna on Tuesday, December 15 at 12:00 noon ET . The Translarna Deep Dive will provide an overview of results from the clinical and real-world
Additional Formats
Dec 04, 2020
SOUTH PLAINFIELD, N.J. , Dec. 4, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 2, 2020 it approved non-statutory stock options to purchase an aggregate of 41,955 shares of its common stock and 20,735 restricted stock units ("RSUs"), each representing
Additional Formats
Dec 04, 2020
SOUTH PLAINFIELD, N.J. , Dec. 4, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval in the Russian Federation for nonsense mutation Duchenne muscular dystrophy (nmDMD).
Additional Formats
Nov 30, 2020
- Third trial initiated in 2020 from compounds identified from PTC's Bio-e platform - SOUTH PLAINFIELD, N.J. , Nov. 30, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in
Additional Formats
Nov 19, 2020
SOUTH PLAINFIELD, N.J. , Nov. 19, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1 st at 11:45 a.m. ET .
Additional Formats